Skip to main content

What is inolimomab (LEUKOTAC®)

What is inolimomab (LEUKOTAC®)?

Inolimomab (LEUKOTAC®) is an immunotherapy monoclonal antibody that targets the interleukin-2 receptor (IL-2), a chemical molecule named cytokine that contributes to the development and proliferation of some white blood cells including T-cells responsible for aGvHD. By linking specifically to the α chain of the receptor (CD25), inolimomab prevents IL-2 from binding on the surface of the donor’s over-active T-cells which blocks their multiplication.

The efficacy of inolimomab in aGvHD lies mainly in its specificity and its preferential affinity to the CD25 receptor found on the surface of T-lymphocytes.

Mode of action of inolimomab (LEUKOTAC®)

Latest news on inolimomab (LEUKOTAC®)

Discover our latest news regarding our pipeline, our partnerships and more

Wed, 04/14/2021 - 07:30 - Sat, 01/19/2030 - 08:30
  • During its first year under ATU and despite the pandemic, around 30 patients in France has been treated with inolimomab as it is consi

Tue, 01/19/2021 - 09:30
  • NOVA awarded €2.4 million to leverage Jinkō®, its best-in-class clinical trial simulation platform, to conduct in silico stud

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

Copyright 2021 ElsaLys Biotech SA

twitter    linkedin

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.